Entering text into the input field will update the search result below

Exact Sciences -- buy signals

Apr. 02, 2011 1:47 PM ETEXAS
Jim Van Meerten profile picture
Jim Van Meerten's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

 This weekend I was screening for a stock to add to the Barchart Van Meerten Speculative portfolio.  This is a portfolio of stocks trading under $10 that are hitting frequent new highs.  I can across  

Exact Sciences (EXAS) .

Exact Sciences (EXAS) uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. The company believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated.
Technical Factors:
  • 88% Barchart technical buy signals
  • Trend Spotter buy signals
  • 16 new highs and up 37.74% in the last month
  • Relative Strength Index 81.71% and rising
  • Trades around 7.30 with a 50 day moving average of 5.80
Add this one to your watch lists.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.